Adenovirus News and Research

RSS

Adenoviruses most commonly cause respiratory illness; however, depending on the infecting serotype, they may also cause various other illnesses, such as gastroenteritis, conjunctivitis, cystitis, and rash illness. Symptoms of respiratory illness caused by adenovirus infection range from the common cold syndrome to pneumonia, croup, and bronchitis. Patients with compromised immune systems are especially susceptible to severe complications of adenovirus infection. Acute respiratory disease (ARD), first recognized among military recruits during World War II, can be caused by adenovirus infections during conditions of crowding and stress.

Exploring vaccine-induced cellular immunity against SARS-CoV-2 Omicron variant

In a new study, researchers determined CD8+ and CD4+ T cell responses against the SARS-CoV-2 Omicron variant in 51 individuals vaccinated with the messenger ribonucleic acid (mRNA)-based Pfizer and adenovirus vector-based Johnson & Johnson vaccines.

5 Jan 2022

Novel insight into the immune characteristics of bats

Many studies have indicated that bats are significant reservoirs of innumerable viruses, such as influenza, coronaviruses, and rabies. These studies have also reported that bats predominantly remain asymptomatic or develop mild diseases during viral infections caused by henipaviruses, Ebola virus, coronaviruses, etc.

4 Jan 2022

Oxford researchers demonstrate the feasibility of increasing the speed and volume of vaccine production

The University of Oxford's vaccine manufacturing research team has today published a pre-print paper demonstrating the feasibility of a step change in the speed and volume of production of adenovirus-vectored vaccines against new virus variants or other future pandemics.

4 Jan 2022

Booster dose of mRNA vaccines found crucial in protecting against SARS-CoV-2 Omicron variants

A new study shows that Omicron is more infectious than any of the other variants and that booster vaccines, especially mRNA vaccines, are capable of neutralizing Omicron variants of pseudoviruses.

29 Dec 2021

An evaluation of the association between COVID vaccination and myocarditis in 42 million people aged 13 or older

A new study posted to the medRxiv* pre-print server included individuals over 13 years of age receiving the third vaccine dose to further evaluate the association between myocarditis and COVID-19 vaccination or infection. The study took place from December 1, 2020, to November 15, 2021.

28 Dec 2021

Ad5-nCoV vaccine safe and effective against symptomatic, severe COVID-19, trials shows

One dose of Ad5-nCoV (Convidecia), a COVID-19 vaccine developed in China, is 57.5% effective against symptomatic COVID-19 and 91.7% effective against severe COVID-19 disease beginning 28 days postvaccination, according to a phase 3 randomized controlled trial published in The Lancet.

23 Dec 2021

Pediatric hospital admissions rise with omicron SARS-CoV-2 variant

A new study examines the impact of the Omicron variant on hospitalizations among children in South Africa.

23 Dec 2021

How COVID vaccines protected Americans against the Delta variant

A new study analyzed the COVID-19 breakthrough case and death rates among fully vaccinated individuals who were 12 years of age or above.

22 Dec 2021

Researchers identify new mechanism for DNA invasion of adenoviral COVID-19 vaccines

Adenoviruses have a linchpin protein that stabilizes their DNA until it reaches the infected cell's nucleus. The protein then detaches from the viral genome, and the virus uncoats. Only then are the genes released into the nucleus, which is necessary for the production of new viruses.

22 Dec 2021

Two-dose ChAdOx1 vaccine protection wanes after three months

New research reported in the journal The Lancet examines the temporal association between the two-dose ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccination regimen and the risk of severe outcomes from COVID-19 in Scotland vs. Brazil, where the Delta variant of SARS-CoV-2 was dominant and rare, respectively.

21 Dec 2021

Production of functional SARS-CoV-2 spike protein in single-cell green alga

A new study uses a novel algal platform for the generation of the SARS-CoV-2 spike protein.

19 Dec 2021

Study says COVID mRNA-based vaccines best for booster vaccination

A new study looks at the adaptive immune response to COVID-19 vaccines, wherein the authors compare heterologous to homologous immunization.

19 Dec 2021

Neutralization potency of COVID-19 vaccine boosters against SARS-CoV-2 variant pseudoviruses

A new study has used this assay to evaluate sera, obtained from 239 individuals vaccinated via any of the above-stated vaccines against SARS-CoV-2’s original strain, the Delta, and Omicron SARS-CoV-2 pseudoviruses.

16 Dec 2021

Signatures of rising SARS-CoV-2 Delta infections in New York

Researchers estimate the probability of breakthrough infections by the Delta variant as compared to other variants.

15 Dec 2021

Changes in trajectory of long COVID symptoms before vaccination

A new preprint describes the results of a study examining this aspect of the disease.

14 Dec 2021

Evaluating the virucidal activity of blue LED light against SARS-CoV-2 infection

A new study provides some possible explanations to the mechanisms by which antiviral activity is exerted by blue LED light and indicated that the alteration of the SARS-CoV-2 spike protein requires the presence of photosensitizers.

13 Dec 2021

Study reveals how a protein in the blood is attracted to key component of Adenovirus-based vaccines

A collaborative team from the School of Medicine at the University of Cardiff, Wales and a range of US institutions used the UK's national synchrotron, Diamond Light Source, to help reveal the details of how a protein in the blood is attracted to a key component of Adenovirus based vaccines.

8 Dec 2021